Nasopharyngeal Carcinoma Screening in Zhongshan City

Zhongshan City People's Hospital

Status: Active, not recruiting

Conditions: Nasopharyngeal Carcinoma

Study type: Observational

Funder types: Other

Identifiers

NCT02501993

NPC-PRO-002

Details and patient eligibility

About

The primary objective is to determine the early diagnosis rate and mortality rate of the Nasopharyngeal Carcinoma (NPC) in the study population.

The secondary objective is to determine the incidence of NPC in the study population.

Full description

The research is to evaluate the effect of NPC screening, also as an extended study of Screening for Nasopharyngeal Carcinoma in High Risk Populations (NCT00941538).

The program was conducted in Xiaolan and Minzhong towns of Zhongshan city in 2012.

All participants will be tested for anti-EBV antibody by using serum samples. Participants are stratified into those having high, moderate and low antibody levels, those having moderate antibody levels are invited to retest annually in the following 3 years and those found to have high antibody levels on these occasions are referred to centers for diagnostic workup for NPC.

Enrollment: 25,000 estimated patients

Sex: All

Ages: 30 to 59 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subject residents in Zhongshan city
• Subject is 30 to 59 years of age inclusive
• Subject has no medical record of nasopharyngeal carcinoma
• ECOG 0-2
• Subject has psychical condition and well consciousness
• Subject is able to comprehend, sign, and date the written informed consent document to participate in the study.

Exclusion criteria

• Subject has heavy cardiovascular, liver or kidney disease
• Subject has medical record of nasopharyngeal carcinoma
• Subject who is not residing in Zhongshan City

Trial design

25,000 participants in 1 patient group

Screening cohort

Description:

All participants will be tested for anti-EBV antibody by using serum samples. Participants are stratified into those having high, moderate and low antibody levels, those having moderate antibody levels are invited to retest annually in the following 3 years and those found to have high antibody levels on these occasions are referred to centers for diagnostic workup for NPC.